Dashboard
Manage Tickers

KALVKalVista Pharmaceuticals, Inc.

Nasdaq kalvista.com


$ 12.32 $ -0.53 (-4.12 %)    

Friday, 06-Sep-2024 15:59:55 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 446.25 $ -12.35 (-2.68 %)
DIA $ 404.28 $ -3.99 (-0.98 %)
SPY $ 539.90 $ -9.25 (-1.68 %)
TLT $ 99.49 $ -0.01 (-0.01 %)
GLD $ 230.65 $ -1.72 (-0.74 %)
$ 12.34
$ 12.32 x 200
$ 12.35 x 200
-- - --
$ 7.21 - $ 16.88
234,664
na
533.28M
$ 1.03
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 09-05-2024 07-31-2024 10-Q
2 07-11-2024 04-30-2024 10-K
3 03-11-2024 01-31-2024 10-Q
4 12-07-2023 10-31-2023 10-Q
5 09-07-2023 07-31-2023 10-Q
6 07-07-2023 04-30-2023 10-K
7 03-09-2023 01-31-2023 10-Q
8 12-08-2022 10-31-2022 10-Q
9 09-08-2022 07-31-2022 10-Q
10 07-07-2022 04-30-2022 10-K
11 03-10-2022 01-31-2022 10-Q
12 12-09-2021 10-31-2021 10-Q
13 09-09-2021 07-31-2021 10-Q
14 07-13-2021 04-30-2021 10-K
15 03-11-2021 01-31-2021 10-Q
16 12-10-2020 10-31-2020 10-Q
17 09-14-2020 07-31-2020 10-Q
18 07-01-2020 04-30-2020 10-K
19 03-10-2020 01-31-2020 10-Q
20 12-03-2019 10-31-2019 10-Q
21 09-09-2019 07-31-2019 10-Q
22 07-16-2019 04-30-2019 10-K
23 03-14-2019 01-31-2019 10-Q
24 12-14-2018 10-31-2018 10-Q
25 09-14-2018 07-31-2018 10-Q
26 07-30-2018 04-30-2018 10-K
27 03-16-2018 01-31-2018 10-Q
28 12-14-2017 10-31-2017 10-Q
29 09-14-2017 07-31-2017 10-Q
30 07-27-2017 04-30-2017 10-K
31 03-16-2017 01-31-2017 10-Q
32 11-08-2016 09-30-2016 10-Q
33 08-12-2016 06-30-2016 10-Q
34 05-12-2016 03-31-2016 10-Q
35 03-30-2016 12-31-2015 10-K
36 11-12-2015 09-30-2015 10-Q
37 08-13-2015 06-30-2015 10-Q
38 05-21-2015 03-31-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

hc-wainwright--co-reiterates-buy-on-kalvista-pharma-maintains-20-price-target
HC Wainwright & Co. Reiterates Buy on KalV...
09/06/2024 11:39:58

HC Wainwright & Co. analyst Andrew Fein reiterates KalVista Pharma (NASDAQ:KALV) with a Buy and maintains $20 price target.

kalvista-presented-additional-analyses-of-efficacy-and-safety-of-sebetralstat-from-phase-2-and-phase-3-double-blind-placebo-controlled-crossover-clinical-trials-as-well-as-interim-data-from-konfident-s--a-phase-3-open-label-extension-trial
KalVista Presented Additional Analyses Of ...
09/06/2024 10:35:41

Data was presented at the Bradykinin Symposium 2024 taking place in Berlin, Germany, on September 5-6. Sebetralstat is a novel,...

needham-reiterates-buy-on-kalvista-pharma-maintains-32-price-target
Needham Reiterates Buy on KalVista Pharma,...
09/06/2024 09:32:41

Needham analyst Serge Belanger reiterates KalVista Pharma (NASDAQ:KALV) with a Buy and maintains $32 price target.

kalvista-pharma-q1-2025-gaap-eps-087-beats-091-estimate-cash-balance-of-1743m
KalVista Pharma Q1 2025 GAAP EPS $(0.87) B...
09/05/2024 10:34:58

kalvistas-sebetralstat-nda-accepted-by-fda-could-be-first-oral-on-demand-hae-treatment-by-mid-2025
KalVista's Sebetralstat NDA Accepted by FD...
09/03/2024 10:32:28

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that the U.S. Food and Drug Administration (FDA) has accepted its...

the-european-medicines-agency-has-validated-the-submission-of-kalvista-pharmaceuticals-marketing-application-seeking-approval-for-sebetralstat-for-the-on-demand-treatment-of-hereditary-angioedema
The European Medicines Agency Has Validate...
08/15/2024 10:35:24

hc-wainwright--co-reiterates-buy-on-kalvista-pharma-maintains-20-price-target
HC Wainwright & Co. Reiterates Buy on KalV...
07/15/2024 10:42:20

HC Wainwright & Co. analyst Andrew Fein reiterates KalVista Pharma (NASDAQ:KALV) with a Buy and maintains $20 price target.

nvidia-to-rally-more-than-33-here-are-10-top-analyst-forecasts-for-friday
NVIDIA To Rally More Than 33%? Here Are 10...
07/12/2024 13:01:36

needham-maintains-buy-on-kalvista-pharma-lowers-price-target-to-32
Needham Maintains Buy on KalVista Pharma, ...
07/12/2024 09:37:24

Needham analyst Serge Belanger maintains KalVista Pharma (NASDAQ:KALV) with a Buy and lowers the price target from $35 to $32.

kalvista-submits-fda-application-for-sebetralstat-phase-3-trial-results-published
KalVista Submits FDA Application for Sebet...
07/11/2024 10:37:03

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today provided an operational update and released financial results for the fisca...

kalvista-pharma-q4-eps-102-misses-073-estimate-cash-balance-of-2104m
KalVista Pharma Q4 EPS $(1.02) Misses $(0....
07/11/2024 10:35:02

kalvista-pharmaceuticals-has-initiated-open-label-konfident-kid-trial-of-sebetralstat-in-pediatric-patients-with-hereditary-angioedema-the-trial-will-enroll-approximately-24-children-aged-2-to-11-years
KalVista Pharmaceuticals Has Initiated Ope...
06/27/2024 10:37:39

If approved, sebetralstat would be the first oral on-demand therapy in pediatric patients aged 2 – 11 years, and only the secon...

needham-reiterates-buy-on-kalvista-pharma-maintains-35-price-target
Needham Reiterates Buy on KalVista Pharma,...
06/18/2024 14:45:59

Needham analyst Serge Belanger reiterates KalVista Pharma (NASDAQ:KALV) with a Buy and maintains $35 price target.

kalvista-submits-new-drug-application-for-fda-review-of-sebetralstat
KalVista Submits New Drug Application For ...
06/18/2024 10:32:18

Sebetralstat is a novel investigational oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema (...

kalvista-pharmaceuticals-presented-us-subgroup-analysis-from-sebetralstat-phase-3-konfident-trial-real-world-claims-and-patient-survey-data-at-eastern-allergy-conference-2024-and-japanese-subgroup-at-annual-meeting-of-japanese-dermatological-association
KalVista Pharmaceuticals Presented US Subg...
06/06/2024 10:35:57

kalvista-highlights-real-world-data-on-hae-treatments-and-patient-experiences-at-eaaci-congress
KalVista Highlights Real-World Data on HAE...
06/03/2024 10:36:32

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that it presented real-world data from US patient surveys that as...

kalvista-pharmaceuticals-presents-late-breaking-phase-3-konfident-trial-data-on-sebetralstat-at-eaaci-congress-nejm-publication-highlights-9-minute-median-time-to-treatment-and-13-hour-symptom-relief-for-laryngeal-attacks-in-konfident-s-trial
KalVista Pharmaceuticals Presents Late-Bre...
05/31/2024 16:17:25

kalvista-pharmaceuticals-says-that-ten-abstracts-accepted-for-presentation-at-the-european-academy-of-allergy-and-clinical-immunology-congress-2024
KalVista Pharmaceuticals Says That Ten Abs...
05/24/2024 10:32:32

The European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024 is taking place in Valencia, Spain from May 31-Ju...

hc-wainwright--co-maintains-buy-on-kalvista-pharma-lowers-price-target-to-20
HC Wainwright & Co. Maintains Buy on KalVi...
05/03/2024 19:44:50

HC Wainwright & Co. analyst Andrew Fein maintains KalVista Pharma (NASDAQ:KALV) with a Buy and lowers the price target f...

needham-reiterates-buy-on-kalvista-pharma-maintains-35-price-target
Needham Reiterates Buy on KalVista Pharma,...
05/01/2024 16:14:49

Needham analyst Serge Belanger reiterates KalVista Pharma (NASDAQ:KALV) with a Buy and maintains $35 price target.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION